Table 2. Slope of Change in Percentage Predicted Slow Vital Capacity (SVC) From Baseline in EMPOWER Placebo Group.

Variable	Observations, No.	Slope (95% CI), Percentage Points per Montha	P Value
Overall	2337	−2.7 (−3.0 to −2.5)	<.001
Age, y
<50	641	−2.3 (−2.7 to −1.8)	.005b
50-65	1164	−2.6 (−2.9 to −2.3)	.007c
>65	532	−3.6 (−4.3 to −2.9)	NA
Sex
Male	1541	−2.6 (−2.9 to −2.3)	.21d
Female	796	−3.0 (−3.3 to −2.6)
Riluzole use
No	517	−3.1 (−3.7 to −2.5)	.65e
Yes	1820	−2.7 (−2.9 to −2.4)
Baseline percentage predicted SVC
<65%	93	−2.2 (−4.2 to −0.3)	.25f
65%-75%	295	−2.8 (−3.6 to −2.1)	.88g
>75%	1949	−2.7 (−3.0 to −2.5)	NA
Site of ALS symptom onset
Bulbar	477	−3.2 (−3.8 to −2.5)	.06h
Other	1860	−2.6 (−2.9 to −2.3)
Baseline ALSFRS-R total score
≤39	1095	−3.1 (−3.4 to −2.8)	<.001i
>39	1242	−2.3 (−2.7 to −1.9)

Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; NA, not applicable.

^aThe slope was estimated using a repeated-measures mixed model and adjustment for baseline SVC.

^bP value for <50 vs >65 years.

^cP value for 50-65 vs >65 years.

^dP value for male vs female.

^eP value for no riluzole use vs riluzole use.

^fP value for <65% vs >75%.

^gP value for 65%-75% vs >75%.

^hP value for bulbar compared with other.

ⁱP value for ≤39 vs >39.